Ashley McEvoy
Ashley McEvoy's purchase track record
Ashley McEvoy has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/21/2026 | PODD | $162K | pending | pending | — |
| 2/20/2026 | PODD | $1.03M | -36.0% | -38.8% | +11.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Johnson & Johnson: Key Takeaways for Long-Term Investors. Recent coverage highlighted three takeaways for long‑term investors in Johnson & Johnson. The article notes the company's steady dividend yield of about 3.1% and its diversified healthcare portfolio. It also points to a relatively high price‑to‑earnings multiple, suggesting expectations of continued growth. These points are relevant as the stock trades near a long‑standing support level.
Transaction History
| PODD | ▲ Buy | Open Market | 1,100 | $162K | 8/21/2026 | View on chart |
| PODD | ▼ Sell | Tax Withholding | 1,411 | $210K | 5/13/2026 | View on chart |
| PODD | ▲ Buy | Grant | 10,046 | $0 | 2/24/2026 | View on chart |
| PODD | ▲ Buy | Open Market | 4,300 | $1.0M | 2/20/2026 | View on chart |
| PODD | ▲ Buy | Grant | 9,540 | $0 | 5/13/2025 | View on chart |
| JNJ | ▼ Sell | Other | 2,787 | $0 | 8/23/2023 | View on chart |
| JNJ | ▲ Buy | Grant | 17,994 | $0 | 2/13/2023 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 7,158 | $1.2M | 2/13/2023 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 2,999 | $0 | 2/10/2023 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 823 | $133K | 2/10/2023 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 73,323 | $5.3M | 11/30/2022 | View on chart |
| JNJ | ▼ Sell | Open Market | 71,923 | $12.6M | 11/30/2022 | View on chart |
| JNJ | ▼ Sell | Open Market | 1,400 | $247K | 11/30/2022 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 15,806 | $0 | 2/15/2022 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 6,242 | $1.0M | 2/15/2022 | View on chart |
| JNJ | ▲ Buy | Option Exercise | 2,885 | $0 | 2/14/2022 | View on chart |
| JNJ | ▼ Sell | Tax Withholding | 792 | $134K | 2/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Insulet Sets Q3 2026 Earnings Date for Nov 4
Insulet has scheduled its third-quarter 2026 financial results for release on November 4, 2026. Recent commentary suggests the company offers affordable growth supported by strong fundamentals. The stock is currently trading near its 52-week low, with technical indicators showing a support rejection and volume spike.
Insulet Sets Q3 2026 Earnings Date for Nov 4. Insulet has scheduled its third-quarter 2026 financial results for release on November 4, 2026. Recent commentary suggests the company offers affordable growth supported by strong fundamentals. The stock is currently trading near its 52-week low, with technical indicators showing a support rejection and volume spike.